KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nu Skin Enterprises (NUS) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Nu Skin Enterprises (NUS) over the last 17 years, with Sep 2025 value amounting to $251.8 million.

  • Nu Skin Enterprises' Cash & Equivalents rose 10.55% to $251.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $251.8 million, marking a year-over-year increase of 10.55%. This contributed to the annual value of $186.9 million for FY2024, which is 27.02% down from last year.
  • Per Nu Skin Enterprises' latest filing, its Cash & Equivalents stood at $251.8 million for Q3 2025, which was down 4.68% from $264.2 million recorded in Q2 2025.
  • Nu Skin Enterprises' Cash & Equivalents' 5-year high stood at $363.9 million during Q2 2022, with a 5-year trough of $186.9 million in Q4 2024.
  • Over the past 3 years, Nu Skin Enterprises' median Cash & Equivalents value was $229.9 million (recorded in 2023), while the average stood at $229.6 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 35.27% in 2023, then rose by 17.80% in 2025.
  • Over the past 5 years, Nu Skin Enterprises' Cash & Equivalents (Quarterly) stood at $339.6 million in 2021, then dropped by 22.05% to $264.7 million in 2022, then fell by 3.27% to $256.1 million in 2023, then declined by 27.02% to $186.9 million in 2024, then rose by 10.55% to $251.8 million in 2025.
  • Its Cash & Equivalents was $251.8 million in Q3 2025, compared to $264.2 million in Q2 2025 and $203.8 million in Q1 2025.